Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 681–690 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 681
- Medicine slug
- gefitinib
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 5
- Source count
- 5
- Agreement rate
- 1
- Recorded readings
48 hours
- Numeric value
- 48
- Unit
- hours
- Source records
- 5
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 5 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3dd135f0-5db1-4236-9756-04533b66dc9d (opens source in a new tab)
Gefitinib label
Version not recorded · Effective date not recorded
Gefitinib is cleared primarily by the liver, with total plasma clearance and elimination half-life of 48 hours after intravenous administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6402435f-9f6a-4f02-91a2-6267d783fa78 (opens source in a new tab)
Gefitinib label
Version not recorded · Effective date not recorded
Gefitinib is cleared primarily by the liver, with total plasma clearance and elimination half-life of 48 hours after intravenous administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1a3c0ce7-06a1-4e04-9106-14ddb2a866a5 (opens source in a new tab)
Gefitinib label
Version not recorded · Effective date not recorded
Gefitinib is cleared primarily by the liver, with total plasma clearance and elimination half-life of 48 hours after intravenous administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0afc12dd-12f8-4def-9027-f38412a862b9 (opens source in a new tab)
Gefitinib label
Version not recorded · Effective date not recorded
Gefitinib is cleared primarily by the liver, with total plasma clearance and elimination half-life of 48 hours after intravenous administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:827d60e8-7e07-41b7-c28b-49ef1c4a5a41 (opens source in a new tab)
Gefitinib label
Version not recorded · Effective date not recorded
Gefitinib is cleared primarily by the liver, with total plasma clearance and elimination half-life of 48 hours after intravenous administration.
Projected row 682
- Medicine slug
- gefitinib
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 5
- Source count
- 5
- Agreement rate
- 1
- Recorded readings
1400 L
- Numeric value
- 1,400
- Unit
- L
- Source records
- 5
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 5 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3dd135f0-5db1-4236-9756-04533b66dc9d (opens source in a new tab)
Gefitinib label
Version not recorded · Effective date not recorded
Gefitinib is extensively distributed throughout the body with a mean steady state volume of distribution of 1400 L following intravenous administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6402435f-9f6a-4f02-91a2-6267d783fa78 (opens source in a new tab)
Gefitinib label
Version not recorded · Effective date not recorded
Gefitinib is extensively distributed throughout the body with a mean steady state volume of distribution of 1400 L following intravenous administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1a3c0ce7-06a1-4e04-9106-14ddb2a866a5 (opens source in a new tab)
Gefitinib label
Version not recorded · Effective date not recorded
Gefitinib is extensively distributed throughout the body with a mean steady state volume of distribution of 1400 L following intravenous administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0afc12dd-12f8-4def-9027-f38412a862b9 (opens source in a new tab)
Gefitinib label
Version not recorded · Effective date not recorded
Gefitinib is extensively distributed throughout the body with a mean steady state volume of distribution of 1400 L following intravenous administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:827d60e8-7e07-41b7-c28b-49ef1c4a5a41 (opens source in a new tab)
Gefitinib label
Version not recorded · Effective date not recorded
Gefitinib is extensively distributed throughout the body with a mean steady state volume of distribution of 1400 L following intravenous administration.
Projected row 683
- Medicine slug
- gemcitabine
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 19
- Source count
- 19
- Agreement rate
- 1
- Recorded readings
50 L
- Numeric value
- 50
- Unit
- L
- Source records
- 19
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 19 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d80176fe-3e8b-48be-87c2-9c603013b3fa (opens source in a new tab)
Gemcitabine label
Version not recorded · Effective date not recorded
Volume of distribution of gemcitabine was 50 L/m 2 following infusions lasting <70 minutes.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44bcc16c-341d-49e8-a1c6-95d084667aca (opens source in a new tab)
Gemcitabine label
Version not recorded · Effective date not recorded
Volume of distribution of gemcitabine was 50 L/m 2 following infusions lasting <70 minutes.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:06dd9d40-74fc-4409-93b1-a46be7126331 (opens source in a new tab)
Gemcitabine label
Version not recorded · Effective date not recorded
Volume of distribution of gemcitabine was 50 L/m 2 following infusions lasting <70 minutes.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a5949d02-29eb-4626-ad35-b7614bb0fa95 (opens source in a new tab)
Gemcitabine label
Version not recorded · Effective date not recorded
Volume of distribution of gemcitabine was 50 L/m 2 following infusions lasting <70 minutes.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dc02a23b-3ff9-4441-aa91-8e9e629a7315 (opens source in a new tab)
Gemcitabine label
Version not recorded · Effective date not recorded
Volume of distribution of gemcitabine was 50 L/m 2 following infusions lasting <70 minutes.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9f8fe5ba-943f-4f0a-9618-6083101faa28 (opens source in a new tab)
Gemcitabine label
Version not recorded · Effective date not recorded
Volume of distribution of gemcitabine was 50 L/m 2 following infusions lasting <70 minutes.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e11eeff7-bcaf-4bf1-8da8-88138e01af84 (opens source in a new tab)
Gemcitabine label
Version not recorded · Effective date not recorded
Volume of distribution of gemcitabine was 50 L/m 2 following infusions lasting <70 minutes.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eafcebc8-ddef-bb6b-fd0a-9d8b9962cdc4 (opens source in a new tab)
Gemcitabine label
Version not recorded · Effective date not recorded
Volume of distribution of gemcitabine was 50 L/m 2 following infusions lasting <70 minutes.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d16907e7-a8c8-4039-ace4-cf4e24ba68c0 (opens source in a new tab)
Gemcitabine label
Version not recorded · Effective date not recorded
Volume of distribution of gemcitabine was 50 L/m 2 following infusions lasting <70 minutes.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a625c92b-c569-4b98-8d2e-2b3f5e12b34f (opens source in a new tab)
Gemcitabine label
Version not recorded · Effective date not recorded
Volume of distribution of gemcitabine was 50 L/m 2 following infusions lasting <70 minutes.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4031017d-d768-46de-8081-476bcb883f5e (opens source in a new tab)
Gemcitabine label
Version not recorded · Effective date not recorded
Volume of distribution of gemcitabine was 50 L/m 2 following infusions lasting <70 minutes.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c0b1b715-9ff8-43ca-9e49-465f1f380084 (opens source in a new tab)
Gemcitabine label
Version not recorded · Effective date not recorded
Volume of distribution of gemcitabine was 50 L/m 2 following infusions lasting <70 minutes.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a6ddaa2f-4c17-430f-a7cd-96b6662923f6 (opens source in a new tab)
Gemcitabine label
Version not recorded · Effective date not recorded
Volume of distribution of gemcitabine was 50 L/m 2 following infusions lasting <70 minutes.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e18ed1cb-7dd0-4001-bfda-17d1f4587fb8 (opens source in a new tab)
Gemcitabine label
Version not recorded · Effective date not recorded
Volume of distribution of gemcitabine was 50 L/m 2 following infusions lasting <70 minutes.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:22af3507-4b4f-4cad-9d61-89ffc4aabbc7 (opens source in a new tab)
Gemcitabine label
Version not recorded · Effective date not recorded
Volume of distribution of gemcitabine was 50 L/m 2 following infusions lasting <70 minutes.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:73ae04d8-38f9-4d3d-b0c2-71d22af1fc86 (opens source in a new tab)
Gemcitabine label
Version not recorded · Effective date not recorded
Volume of distribution of gemcitabine was 50 L/m 2 following infusions lasting <70 minutes.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c550dd16-a5e8-44be-87f2-210c15bbb513 (opens source in a new tab)
Gemcitabine label
Version not recorded · Effective date not recorded
Volume of distribution of gemcitabine was 50 L/m 2 following infusions lasting <70 minutes.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5af49a48-f1c0-467d-b5da-ac9f1ae8e34c (opens source in a new tab)
Gemcitabine label
Version not recorded · Effective date not recorded
Volume of distribution of gemcitabine was 50 L/m 2 following infusions lasting <70 minutes.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d1f3951c-d13f-4662-ad4b-ecfc07f59104 (opens source in a new tab)
Gemcitabine label
Version not recorded · Effective date not recorded
Volume of distribution of gemcitabine was 50 L/m 2 following infusions lasting <70 minutes.
Projected row 684
- Medicine slug
- gemfibrozil
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 44
- Source count
- 44
- Agreement rate
- 1
- Recorded readings
1.5 hours
- Numeric value
- 1.5
- Unit
- hours
- Source records
- 44
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 44 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4260d746-bb58-4e10-9ffe-fc414f22b591 (opens source in a new tab)
Gemfibrozil label
Version not recorded · Effective date not recorded
Peak plasma levels occur in 1 to 2 hours with a plasma half-life of 1.5 hours following multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a95264ab-eb86-7699-e053-2995a90a3d1f (opens source in a new tab)
Gemfibrozil label
Version not recorded · Effective date not recorded
Peak plasma levels occur in 1 to 2 hours with a plasma half-life of 1.5 hours following multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:30a0d14a-f7a7-4ecf-99cd-6b907c8e0fe8 (opens source in a new tab)
Gemfibrozil label
Version not recorded · Effective date not recorded
Peak plasma levels occur in 1 to 2 hours with a plasma half-life of 1.5 hours following multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0b50849a-66b6-4e8f-9f45-5425a875d366 (opens source in a new tab)
Gemfibrozil label
Version not recorded · Effective date not recorded
Peak plasma levels occur in 1 to 2 hours with a plasma half-life of 1.5 hours following multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6a2362a-21e1-442d-9f5d-9e600b5a2ea8 (opens source in a new tab)
Gemfibrozil label
Version not recorded · Effective date not recorded
Peak plasma levels occur in 1 to 2 hours with a plasma half-life of 1.5 hours following multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5501438d-5247-4f2a-8e15-085276d01725 (opens source in a new tab)
Gemfibrozil label
Version not recorded · Effective date not recorded
Peak plasma levels occur in 1 to 2 hours with a plasma half-life of 1.5 hours following multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:556945e8-4100-4538-bcba-af5b2f13a7e8 (opens source in a new tab)
Gemfibrozil label
Version not recorded · Effective date not recorded
Peak plasma levels occur in 1 to 2 hours with a plasma half-life of 1.5 hours following multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:17529d33-f24a-1f3f-e063-6394a90ae374 (opens source in a new tab)
Gemfibrozil label
Version not recorded · Effective date not recorded
Peak plasma levels occur in 1 to 2 hours with a plasma half-life of 1.5 hours following multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2fc2c8fe-6158-4e4d-9753-dc2be1b10f42 (opens source in a new tab)
Gemfibrozil label
Version not recorded · Effective date not recorded
Peak plasma levels occur in 1 to 2 hours with a plasma half-life of 1.5 hours following multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e6bc1a4f-2a4f-4fdf-8084-488ec8b8b7ab (opens source in a new tab)
Gemfibrozil label
Version not recorded · Effective date not recorded
Peak plasma levels occur in 1 to 2 hours with a plasma half-life of 1.5 hours following multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:75cac02c-56e3-4dfe-b1e2-4ce166b28833 (opens source in a new tab)
Gemfibrozil label
Version not recorded · Effective date not recorded
Peak plasma levels occur in 1 to 2 hours with a plasma half-life of 1.5 hours following multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3ebb5947-1fe5-9740-6a4b-1f8b577b2711 (opens source in a new tab)
Gemfibrozil label
Version not recorded · Effective date not recorded
Peak plasma levels occur in 1 to 2 hours with a plasma half-life of 1.5 hours following multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e52c9c88-8197-48b4-88cb-1b4b22ceaf16 (opens source in a new tab)
Gemfibrozil label
Version not recorded · Effective date not recorded
Peak plasma levels occur in 1 to 2 hours with a plasma half-life of 1.5 hours following multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fe98f68c-7182-4a88-93a5-cbdbb37fb8c2 (opens source in a new tab)
Gemfibrozil label
Version not recorded · Effective date not recorded
Peak plasma levels occur in 1 to 2 hours with a plasma half-life of 1.5 hours following multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a68f430e-7c98-4bd9-8902-758706713996 (opens source in a new tab)
Gemfibrozil label
Version not recorded · Effective date not recorded
Peak plasma levels occur in 1 to 2 hours with a plasma half-life of 1.5 hours following multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:58c1f50b-9f84-42fe-b7dd-6eece286e28b (opens source in a new tab)
Gemfibrozil label
Version not recorded · Effective date not recorded
Peak plasma levels occur in 1 to 2 hours with a plasma half-life of 1.5 hours following multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bfddc3bd-c2dc-449e-e053-2a95a90a8adc (opens source in a new tab)
Gemfibrozil label
Version not recorded · Effective date not recorded
Peak plasma levels occur in 1 to 2 hours with a plasma half-life of 1.5 hours following multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:415ac7e0-ddc7-453e-e054-00144ff8d46c (opens source in a new tab)
Gemfibrozil label
Version not recorded · Effective date not recorded
Peak plasma levels occur in 1 to 2 hours with a plasma half-life of 1.5 hours following multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5c09fe54-697e-4cd5-9a26-7c9c7fa9a864 (opens source in a new tab)
Gemfibrozil label
Version not recorded · Effective date not recorded
Peak plasma levels occur in 1 to 2 hours with a plasma half-life of 1.5 hours following multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b8bb442e-66dc-435e-830c-4ba3daa47c04 (opens source in a new tab)
Gemfibrozil label
Version not recorded · Effective date not recorded
Peak plasma levels occur in 1 to 2 hours with a plasma half-life of 1.5 hours following multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4e9e08da-9700-4934-a2b1-4f64c70ea8a2 (opens source in a new tab)
Gemfibrozil label
Version not recorded · Effective date not recorded
Peak plasma levels occur in 1 to 2 hours with a plasma half-life of 1.5 hours following multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fe91d458-1877-4c2e-aa15-efd802e6741f (opens source in a new tab)
Gemfibrozil label
Version not recorded · Effective date not recorded
Peak plasma levels occur in 1 to 2 hours with a plasma half-life of 1.5 hours following multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b5e33ee2-f766-41d6-8a4b-7b4f0e961bf4 (opens source in a new tab)
Gemfibrozil label
Version not recorded · Effective date not recorded
Peak plasma levels occur in 1 to 2 hours with a plasma half-life of 1.5 hours following multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:929d6a30-ab06-4b43-9147-ab2cc613b41f (opens source in a new tab)
Gemfibrozil label
Version not recorded · Effective date not recorded
Peak plasma levels occur in 1 to 2 hours with a plasma half-life of 1.5 hours following multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a086fc16-e6f3-47fd-b577-7c611e735834 (opens source in a new tab)
Gemfibrozil label
Version not recorded · Effective date not recorded
Peak plasma levels occur in 1 to 2 hours with a plasma half-life of 1.5 hours following multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16d0326a-a55b-448b-be24-a16182aaef5a (opens source in a new tab)
Gemfibrozil label
Version not recorded · Effective date not recorded
Peak plasma levels occur in 1 to 2 hours with a plasma half-life of 1.5 hours following multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eb1a2edf-587e-42c5-a98b-58646bc3f948 (opens source in a new tab)
Gemfibrozil label
Version not recorded · Effective date not recorded
Peak plasma levels occur in 1 to 2 hours with a plasma half-life of 1.5 hours following multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1967afce-ce55-4b10-bd8c-e4e94130de87 (opens source in a new tab)
Gemfibrozil label
Version not recorded · Effective date not recorded
Peak plasma levels occur in 1 to 2 hours with a plasma half-life of 1.5 hours following multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:394dfb45-cd3c-4e1e-8dd6-7e4867e90a03 (opens source in a new tab)
Gemfibrozil label
Version not recorded · Effective date not recorded
Peak plasma levels occur in 1 to 2 hours with a plasma half-life of 1.5 hours following multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5738f713-d4b4-437c-b931-fb3b2c22f6d3 (opens source in a new tab)
Gemfibrozil label
Version not recorded · Effective date not recorded
Peak plasma levels occur in 1 to 2 hours with a plasma half-life of 1.5 hours following multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:54c65a5d-2ff9-493a-90d9-2cff48d1a072 (opens source in a new tab)
Gemfibrozil label
Version not recorded · Effective date not recorded
Peak plasma levels occur in 1 to 2 hours with a plasma half-life of 1.5 hours following multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:efecc680-f626-46bf-bc2b-3b5a72ba0267 (opens source in a new tab)
Gemfibrozil label
Version not recorded · Effective date not recorded
Peak plasma levels occur in 1 to 2 hours with a plasma half-life of 1.5 hours following multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:592811f2-e231-6a58-e053-2991aa0a69a9 (opens source in a new tab)
Gemfibrozil label
Version not recorded · Effective date not recorded
Peak plasma levels occur in 1 to 2 hours with a plasma half-life of 1.5 hours following multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:42e40524-57e9-4fee-993f-be0fda14936b (opens source in a new tab)
Gemfibrozil label
Version not recorded · Effective date not recorded
Peak plasma levels occur in 1 to 2 hours with a plasma half-life of 1.5 hours following multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7dbd38ab-7965-463f-9f8e-70efa8e071fb (opens source in a new tab)
Gemfibrozil label
Version not recorded · Effective date not recorded
Peak plasma levels occur in 1 to 2 hours with a plasma half-life of 1.5 hours following multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:509e6e7c-bb54-f135-e063-6294a90a5279 (opens source in a new tab)
Gemfibrozil label
Version not recorded · Effective date not recorded
Peak plasma levels occur in 1 to 2 hours with a plasma half-life of 1.5 hours following multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c48855b7-215e-453b-b3b1-a0f9dee7221f (opens source in a new tab)
Gemfibrozil label
Version not recorded · Effective date not recorded
Peak plasma levels occur in 1 to 2 hours with a plasma half-life of 1.5 hours following multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e3ef1638-4c2b-4f74-af31-52c081619963 (opens source in a new tab)
Gemfibrozil label
Version not recorded · Effective date not recorded
Peak plasma levels occur in 1 to 2 hours with a plasma half-life of 1.5 hours following multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8f36abfa-dc52-4c99-8a4a-b0cb80c3249a (opens source in a new tab)
Gemfibrozil label
Version not recorded · Effective date not recorded
Peak plasma levels occur in 1 to 2 hours with a plasma half-life of 1.5 hours following multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2cb2de4d-8261-46d8-ae63-c572fdc887d4 (opens source in a new tab)
Gemfibrozil label
Version not recorded · Effective date not recorded
Peak plasma levels occur in 1 to 2 hours with a plasma half-life of 1.5 hours following multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:05bfbcdc-03ab-4fba-9582-980602410ef9 (opens source in a new tab)
Gemfibrozil label
Version not recorded · Effective date not recorded
Peak plasma levels occur in 1 to 2 hours with a plasma half-life of 1.5 hours following multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2f5738ac-1c9c-4f3a-8c7d-6039d768831e (opens source in a new tab)
Gemfibrozil label
Version not recorded · Effective date not recorded
Peak plasma levels occur in 1 to 2 hours with a plasma half-life of 1.5 hours following multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4907bbfa-27f4-4569-8957-9704f9c998a0 (opens source in a new tab)
Gemfibrozil label
Version not recorded · Effective date not recorded
Peak plasma levels occur in 1 to 2 hours with a plasma half-life of 1.5 hours following multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7379a1c1-d34f-4eb8-acb8-c5cbaea0f017 (opens source in a new tab)
Gemfibrozil label
Version not recorded · Effective date not recorded
Peak plasma levels occur in 1 to 2 hours with a plasma half-life of 1.5 hours following multiple doses.
Projected row 685
- Medicine slug
- glimepiride
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 73
- Source count
- 73
- Agreement rate
- 1
- Recorded readings
99.5%
- Numeric value
- 99.5
- Unit
- %
- Source records
- 73
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 73 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:489dc098-0ac7-4f8e-b258-326229539c7c (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8f687fa6-54eb-4556-8ea6-aafec49a87d1 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fd26934e-daea-f47b-e053-6394a90a4bc6 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c994796e-dd3d-4f40-a8f2-d317f55e34d5 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:657f1b51-2f82-44f6-a23d-97f4b34b3c45 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:86acdd9e-8637-43e4-8bf7-b3a123b871b8 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0a1eaf23-d5fd-4b3e-96c5-68ff16f0033b (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:def20e38-01f7-4ead-beb6-3dc11062a342 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ebb9f080-b11d-5d18-36f0-627107e7fbcd (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:95c59026-a2db-4579-b58c-b0a8e12e7f84 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0003458f-352a-46fa-9d99-230daa76ae29 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2794f86b-d521-414b-8154-5dd1e2519653 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51157849-7990-4a8b-ae50-eda1baf93cfa (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:661b5b13-6334-4965-8dc5-709e19080584 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:49bf2d48-efa8-487b-b861-0124c3a4c951 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1b3c7d74-f80b-4fb1-8dca-66880af5d3fc (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dae404ac-881a-14d8-e053-2995a90acd41 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:62780d2e-083d-4bcb-99ff-1b1b4ade60d9 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:90d675cb-6def-49a3-b8b4-229f19d6b617 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:647a146c-c752-4589-8619-aed5c720ca54 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b6ce0eea-149d-4aed-a615-0b1c8f3f6a8e (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e8da2484-43a7-4dcb-84d5-d84596feb9f6 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a9461830-1c4f-4bc4-b622-1c44112a76b9 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:48ada723-8144-497d-afd6-a8c52a1dd3ff (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf8e5993-5ee7-d26d-e053-2a95a90ae5df (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e81a39a-30bb-4d6d-82e1-17d7134365be (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:744a5cca-7863-491a-b43a-1b649791702c (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cc2bc07f-3fab-4df1-85cc-dc0c8e60b4fa (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f69e36b9-4940-4f01-b5ea-59dc66dc1e87 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:669a67c2-2f97-4b7e-8bba-83a015e0fa94 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:230949fd-563e-8dbf-e063-6394a90ab9b6 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:10a36c79-1b24-46b7-e063-6294a90a8dca (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:93f1e064-fcbd-e8fd-e053-2995a90a5dbb (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:72d88c6d-2f0a-4bf8-aa7f-1e1811794187 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:abc187f1-8645-23e9-e053-2a95a90a64a7 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:101cdc41-2131-4425-b550-6a0a60b5f4a4 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dbed06f9-7758-4c96-9af0-1ed6103db7df (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9e863f84-d6f2-4d61-8250-774569e84353 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:248c3cb3-4501-4b85-bd1d-0624b6afda2c (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:28eefc95-d92e-4555-b6c5-2933860b0610 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:60e9397e-83b9-489e-9683-6f87e458bbaa (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:01196f54-32c8-41a0-b0ed-7968ca5d2fa2 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1c335fc7-24d0-5526-e063-6394a90a488e (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:07ad4366-4b21-f633-49f3-c2b35f88168d (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:41bf4a72-9288-50a1-e063-6394a90a5e7c (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1450f455-a14a-4f9b-b3aa-dae49ea0c186 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a01b0466-13f5-4c47-ae55-c5f1527d9414 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4f83e203-c102-47fa-bb8e-4fc5541e0d6f (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1e5d562e-b3bf-4502-adc8-c89c8818a9bc (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cdeda274-955b-413d-b2d4-b14d94f7d20c (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a11680ba-2750-43ab-a1b1-a52ebe3e139f (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:00b9e312-921e-41e6-ad27-0a6ce87f8298 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5a5747ea-cded-49ed-8807-dd3e2a1159e0 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:be772fca-1579-4fba-a4b7-04b970d09e45 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1f102e4c-1954-4f17-8c60-4dad79f25a25 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0c25c987-856f-448d-903a-e2c94049b0a7 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:11ae3189-6139-4470-95d5-72abc0f5b0d0 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e12ab052-e3d6-4246-b727-f1e3f9057f09 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:68cb4fcd-5bc3-4f53-9085-86df6a4246d6 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d4513181-4558-4d9a-851b-acf7e3eda25a (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:be7175ae-ba53-45b8-9554-e4f4ebf56883 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9b74fbac-9e04-4927-9981-1e3dace89c6d (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f3184cd3-df99-db32-e053-2995a90aa573 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f2f2d6da-eb40-4290-e053-2a95a90a6ca0 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:35ba31ef-2b90-61c6-e063-6394a90a59ee (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:beb0cefb-807b-4cc3-ada2-7a8ed4aa8f2b (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0b12d4ab-fa0c-44d5-888c-265dbb661561 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8ff0de99-272e-4e68-9caf-69f3f146ac29 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:79ee7533-f75d-4c49-b396-b339654f5c44 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f4ffb19e-6d65-49fd-83ce-514d38d9d97c (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:58c4261e-e98f-4280-9562-2800956dff14 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ed7a3a8e-97dd-4a5a-9497-001acfd2f1f0 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fc9d8495-184c-3af1-e053-6394a90a5e29 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Protein binding was greater than 99.5%.
Projected row 686
- Medicine slug
- glimepiride
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 73
- Source count
- 73
- Agreement rate
- 1
- Recorded readings
8.8 L
- Numeric value
- 8.8
- Unit
- L
- Source records
- 73
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 73 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:489dc098-0ac7-4f8e-b258-326229539c7c (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8f687fa6-54eb-4556-8ea6-aafec49a87d1 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fd26934e-daea-f47b-e053-6394a90a4bc6 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c994796e-dd3d-4f40-a8f2-d317f55e34d5 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:657f1b51-2f82-44f6-a23d-97f4b34b3c45 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:86acdd9e-8637-43e4-8bf7-b3a123b871b8 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0a1eaf23-d5fd-4b3e-96c5-68ff16f0033b (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:def20e38-01f7-4ead-beb6-3dc11062a342 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ebb9f080-b11d-5d18-36f0-627107e7fbcd (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:95c59026-a2db-4579-b58c-b0a8e12e7f84 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0003458f-352a-46fa-9d99-230daa76ae29 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2794f86b-d521-414b-8154-5dd1e2519653 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution: After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51157849-7990-4a8b-ae50-eda1baf93cfa (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:661b5b13-6334-4965-8dc5-709e19080584 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:49bf2d48-efa8-487b-b861-0124c3a4c951 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1b3c7d74-f80b-4fb1-8dca-66880af5d3fc (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution: After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dae404ac-881a-14d8-e053-2995a90acd41 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:62780d2e-083d-4bcb-99ff-1b1b4ade60d9 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:90d675cb-6def-49a3-b8b4-229f19d6b617 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:647a146c-c752-4589-8619-aed5c720ca54 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution: After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b6ce0eea-149d-4aed-a615-0b1c8f3f6a8e (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e8da2484-43a7-4dcb-84d5-d84596feb9f6 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a9461830-1c4f-4bc4-b622-1c44112a76b9 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:48ada723-8144-497d-afd6-a8c52a1dd3ff (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf8e5993-5ee7-d26d-e053-2a95a90ae5df (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e81a39a-30bb-4d6d-82e1-17d7134365be (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution: After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:744a5cca-7863-491a-b43a-1b649791702c (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cc2bc07f-3fab-4df1-85cc-dc0c8e60b4fa (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f69e36b9-4940-4f01-b5ea-59dc66dc1e87 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:669a67c2-2f97-4b7e-8bba-83a015e0fa94 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:230949fd-563e-8dbf-e063-6394a90ab9b6 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:10a36c79-1b24-46b7-e063-6294a90a8dca (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:93f1e064-fcbd-e8fd-e053-2995a90a5dbb (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:72d88c6d-2f0a-4bf8-aa7f-1e1811794187 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution: After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:abc187f1-8645-23e9-e053-2a95a90a64a7 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:101cdc41-2131-4425-b550-6a0a60b5f4a4 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution: After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dbed06f9-7758-4c96-9af0-1ed6103db7df (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9e863f84-d6f2-4d61-8250-774569e84353 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution: After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:248c3cb3-4501-4b85-bd1d-0624b6afda2c (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:28eefc95-d92e-4555-b6c5-2933860b0610 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:60e9397e-83b9-489e-9683-6f87e458bbaa (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:01196f54-32c8-41a0-b0ed-7968ca5d2fa2 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1c335fc7-24d0-5526-e063-6394a90a488e (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:07ad4366-4b21-f633-49f3-c2b35f88168d (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:41bf4a72-9288-50a1-e063-6394a90a5e7c (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1450f455-a14a-4f9b-b3aa-dae49ea0c186 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a01b0466-13f5-4c47-ae55-c5f1527d9414 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4f83e203-c102-47fa-bb8e-4fc5541e0d6f (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution: After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1e5d562e-b3bf-4502-adc8-c89c8818a9bc (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cdeda274-955b-413d-b2d4-b14d94f7d20c (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a11680ba-2750-43ab-a1b1-a52ebe3e139f (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:00b9e312-921e-41e6-ad27-0a6ce87f8298 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution : After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5a5747ea-cded-49ed-8807-dd3e2a1159e0 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution: After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:be772fca-1579-4fba-a4b7-04b970d09e45 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1f102e4c-1954-4f17-8c60-4dad79f25a25 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0c25c987-856f-448d-903a-e2c94049b0a7 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:11ae3189-6139-4470-95d5-72abc0f5b0d0 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution: After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e12ab052-e3d6-4246-b727-f1e3f9057f09 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:68cb4fcd-5bc3-4f53-9085-86df6a4246d6 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution: After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d4513181-4558-4d9a-851b-acf7e3eda25a (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:be7175ae-ba53-45b8-9554-e4f4ebf56883 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9b74fbac-9e04-4927-9981-1e3dace89c6d (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution: After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f3184cd3-df99-db32-e053-2995a90aa573 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f2f2d6da-eb40-4290-e053-2a95a90a6ca0 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution: After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:35ba31ef-2b90-61c6-e063-6394a90a59ee (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:beb0cefb-807b-4cc3-ada2-7a8ed4aa8f2b (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution: After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0b12d4ab-fa0c-44d5-888c-265dbb661561 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8ff0de99-272e-4e68-9caf-69f3f146ac29 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:79ee7533-f75d-4c49-b396-b339654f5c44 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f4ffb19e-6d65-49fd-83ce-514d38d9d97c (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution: After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:58c4261e-e98f-4280-9562-2800956dff14 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution: After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ed7a3a8e-97dd-4a5a-9497-001acfd2f1f0 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution: After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fc9d8495-184c-3af1-e053-6394a90a5e29 (opens source in a new tab)
Glimepiride label
Version not recorded · Effective date not recorded
Distribution After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min.
Projected row 687
- Medicine slug
- glipizide
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 107
- Source count
- 30
- Agreement rate
- 1
- Recorded readings
100%
- Numeric value
- 100
- Unit
- %
- Source records
- 30
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 30 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0effd04d-172c-5d8c-e063-6294a90a93f4 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of glipizide was 100% after single oral doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ab2f4ea6-46e8-268a-e053-2995a90a3977 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The relationship between dose and reduction in hemoglobin A1c was not established, however subjects treated with 20 mg had a greater reduction in fasting plasma glucose compared to subjects treated with 5 mg. 12.3 Pharmacokinetics Absorption The absolute bioavailability of glipizide was 100% after single oral doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5014a2d7-e0d3-4e84-9a3e-c90b398b8c6c (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of glipizide was 100% after single oral doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4982f018-c53c-48ec-a4e8-4834228bcf2c (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The relationship between dose and reduction in hemoglobin A1c was not established, however subjects treated with 20 mg had a greater reduction in fasting plasma glucose compared to subjects treated with 5 mg. 12.3 Pharmacokinetics Absorption The absolute bioavailability of glipizide was 100% after single oral doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:08b01608-73c2-45e0-8de4-c6c401261152 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of glipizide was 100% after single oral doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bde478e6-e290-47e0-9241-ce88d927633e (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The relationship between dose and reduction in hemoglobin A1c was not established, however subjects treated with 20 mg had a greater reduction in fasting plasma glucose compared to subjects treated with 5 mg. 12.3 Pharmacokinetics Absorption The absolute bioavailability of glipizide was 100% after single oral doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff9b3b7a-5ab1-45ec-e053-6294a90af426 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The relationship between dose and reduction in hemoglobin A1c was not established, however subjects treated with 20 mg had a greater reduction in fasting plasma glucose compared to subjects treated with 5 mg. 12.3 Pharmacokinetics Absorption The absolute bioavailability of glipizide was 100% after single oral doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:548c1f50-dbf0-49cc-b58b-fcc5937affa8 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The relationship between dose and reduction in hemoglobin A1c was not established, however subjects treated with 20 mg had a greater reduction in fasting plasma glucose compared to subjects treated with 5 mg. 12.3 Pharmacokinetics Absorption The absolute bioavailability of glipizide was 100% after single oral doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1b2ef6e2-5e7c-761e-e063-6294a90addd0 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of glipizide was 100% after single oral doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:915636a4-092e-4e2e-9bc0-0d387d996977 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of glipizide was 100% after single oral doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e593552f-9817-4cb5-b491-31ea57dea4b8 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of glipizide was 100% after single oral doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:667dd68a-d3e7-4b50-bd0a-d17783a090d5 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of glipizide was 100% after single oral doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aaf029d3-027e-4ae8-8ec5-3a4c16f9bd28 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of glipizide was 100% after single oral doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:84794a52-b717-488c-8533-6425c83d405f (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of glipizide was 100% after single oral doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:695c178f-77f0-451e-b718-72b65e495b7e (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of glipizide was 100% after single oral doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0338aff9-29f9-405e-b516-06ef4b863863 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The relationship between dose and reduction in hemoglobin A1c was not established, however subjects treated with 20 mg had a greater reduction in fasting plasma glucose compared to subjects treated with 5 mg. 12.3 Pharmacokinetics Absorption The absolute bioavailability of glipizide was 100% after single oral doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4afa67b2-7f86-4189-93a5-6a605f74540d (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of glipizide was 100% after single oral doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0df8f606-97b3-463c-a132-338cf4630a71 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of glipizide was 100% after single oral doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a34b58ac-42b2-4a19-a28b-cb3144ea55cd (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The relationship between dose and reduction in hemoglobin A1c was not established, however subjects treated with 20 mg had a greater reduction in fasting plasma glucose compared to subjects treated with 5 mg. 12.3 Pharmacokinetics Absorption The absolute bioavailability of glipizide was 100% after single oral doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2aa01a7e-a703-426f-9cd3-70b88d0a8e7f (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of glipizide was 100% after single oral doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0ffe361a-c99b-4f68-a7e2-a67a71c0c496 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The relationship between dose and reduction in hemoglobin A1c was not established, however subjects treated with 20 mg had a greater reduction in fasting plasma glucose compared to subjects treated with 5 mg. 12.3 Pharmacokinetics Absorption The absolute bioavailability of glipizide was 100% after single oral doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:03151cb5-d32b-4484-8f2a-8c5d24c7f6f1 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The relationship between dose and reduction in hemoglobin A1c was not established, however subjects treated with 20 mg had a greater reduction in fasting plasma glucose compared to subjects treated with 5 mg. 12.3 Pharmacokinetics Absorption The absolute bioavailability of glipizide was 100% after single oral doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0a1e1152-ade7-2092-e063-6394a90a99e7 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of glipizide was 100% after single oral doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e4831ddb-9680-40cb-a060-4ba77c52d0aa (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of glipizide was 100% after single oral doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:15308fc4-11e3-4cd5-8f04-ab8e3433cc7d (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of glipizide was 100% after single oral doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ceb86ebb-d00a-4261-90ad-8751e799d93c (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of glipizide was 100% after single oral doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4632b4ec-d2f1-40cc-8ef4-256413d8dbec (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The relationship between dose and reduction in hemoglobin A1c was not established, however subjects treated with 20 mg had a greater reduction in fasting plasma glucose compared to subjects treated with 5 mg. 12.3 Pharmacokinetics Absorption The absolute bioavailability of glipizide was 100% after single oral doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c2aadc88-22d2-467c-b2cb-03efb5a1f1c1 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The relationship between dose and reduction in hemoglobin A1c was not established, however subjects treated with 20 mg had a greater reduction in fasting plasma glucose compared to subjects treated with 5 mg. 12.3 Pharmacokinetics Absorption The absolute bioavailability of glipizide was 100% after single oral doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eed99b60-d043-4249-9b2a-f05e46fb588d (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of glipizide was 100% after single oral doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0ccc17ca-fff8-0449-e063-6294a90af36d (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of glipizide was 100% after single oral doses in patients with type 2 diabetes mellitus.
Projected row 688
- Medicine slug
- glipizide
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 107
- Source count
- 107
- Agreement rate
- 0.719626
- Recorded readings
2 to 4 hours
- Numeric value
- 2
- Unit
- hours
- Source records
- 77
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 77 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:560448dd-3690-43d9-9667-925f20bb816e (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2 to 4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:95ea4c96-84b9-4515-9494-a93d26820f70 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2–4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f620559f-985b-421f-98df-bc2ca1cb0ece (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2 to 4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8c27962d-626b-30e6-e053-2a95a90a49c6 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2 to 4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dcf426b8-bcdc-8214-a1b6-6388bd3399a0 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2 to 4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3d87cc75-7a0d-46a2-e063-6294a90a6d49 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2–4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4d490a3a-abdc-4ff4-83fb-f302f51e3023 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2–4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c829b7bf-1a12-44b2-b5ce-fd44a1f0d333 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2 to 4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5ca7e38b-84cb-4043-b97e-e2f5cd82b442 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2–4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e0de2d19-b24b-46af-a10e-0b78c51350a4 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2–4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:abab5b07-08eb-4416-ae03-3656a078caa2 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2 to 4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:64c2a82f-014c-47d7-b303-23531e6bb723 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2 to 4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:213c4e61-9bb7-9d1b-e063-6394a90a7339 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2 to 4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:87cd4930-ba68-4acf-bf74-619c477b557d (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2–4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3b111484-78ef-4db9-95ee-6cc4b6acdd59 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2–4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0ed5ed22-dd53-495d-bc10-0bede4d87926 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2 to 4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e954afb8-52eb-416a-8f1b-14b0fcb3bac2 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2–4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d3b5677c-2265-47c8-beeb-bf12106056ba (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2 to 4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1b2e5656-9da9-4fab-bf01-ed75896b836a (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2 to 4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d6c016f7-bf93-4322-a179-d4798234b381 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2 to 4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c16edad6-4271-6ff0-e053-2a95a90a0240 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2 to 4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:06fb6c56-5609-41d9-8389-eba81432218d (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2–4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:62d569b8-bb34-0e06-e053-2a91aa0a2ae1 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2 to 4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:383540fd-2931-49bf-8009-25e8f7fc9bda (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2 to 4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a38cfe61-4aa5-498c-bca5-03a8213303bb (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2 to 4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9c9a3688-6de9-41db-af82-c4aa9b5b3f92 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2 to 4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51b35391-7672-c02f-e063-6294a90af54e (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2 to 4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c4dfe64-d1c5-65ec-e063-6394a90aead5 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2–4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:99af53db-e102-427a-a5a2-be1e69b3152d (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2 to 4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16fb8bc7-1db1-477e-a201-b3b678b8a84c (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2 to 4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6427db20-6783-439f-8c2d-64d1a6fcb9fc (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2–4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9f7f880a-1060-431a-a155-884e8cfbdf22 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2 to 4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f280acc1-d912-4f2e-b131-440e708c7b1f (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2 to 4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:be20727f-2724-457a-89ac-aa96604a0015 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2 to 4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aa1b16bf-e01c-d539-e053-2995a90a2735 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2 to 4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c8cfd137-7b41-460f-a463-141c9d1985ff (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2–4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:53e650f1-f755-e3ad-e063-6294a90ae309 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2 to 4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d91d021f-f644-eac7-e053-2995a90a81c4 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2 to 4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a59e2aaf-692c-4696-817b-3fed7a9dc52c (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2 to 4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f5d7a98c-d1d4-43b9-8d7e-830a33ae0c24 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2–4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:afb65cc1-a4fb-4771-b09c-dcf6e8c5786e (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2 to 4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0b29837b-c39b-16d2-e063-6394a90abe61 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2 to 4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6282c653-9e9c-6810-e053-2991aa0a4a8e (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2 to 4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c0db4c38-6eed-49ca-84ab-7ed89e476822 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2 to 4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c582d7d0-4db0-4296-8131-baefd1a671b2 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2–4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:589dc76d-c347-0589-e053-2991aa0a2520 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2 to 4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e295cbc-37c1-4e25-e054-00144ff8d46c (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2 to 4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5c627a52-e4ca-7103-e053-2a91aa0ae13f (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2 to 4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:155216cf-4bad-479a-83b6-032d4bd11c2e (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2–4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:02857195-33e9-4c1f-9e5f-7cc62f283649 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2 to 4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3de8b0a7-b848-40af-8406-fe6924ff41db (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2–4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ad55dfd7-ffb5-478a-aa84-1009fa921e22 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2 to 4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf5ff427-3ee4-4064-a55e-35daa2f12a06 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2 to 4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:86e6583c-b290-e2b5-e053-2991aa0ab485 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2 to 4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d5398166-5698-4ee5-bd41-3c24e4445b53 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2 to 4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:00729e82-150a-464a-abe7-a3319721fbdb (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2 to 4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9b405ff3-6ce5-460a-9406-db92e0e6ab1b (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2–4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:376ce3cf-4e1b-4b5f-b3e7-cc9fc4a5aeb4 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2 to 4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9b6464f-6fe6-446e-8150-d0c15c46fee8 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2–4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f60b0690-aca9-40ec-956e-bd2ecc35ec54 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2 to 4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4995328f-287c-4d4a-9b5f-9d354cc530fb (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2 to 4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b31ab6dd-0277-43ee-a054-f20c462f0c56 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2 to 4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3bb3b80a-30e8-62fe-e054-00144ff8d46c (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2 to 4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:116ffc6a-735c-49e0-a9d5-69b6bc3e3706 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2 to 4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:69a21bd3-3364-4035-b098-3808cc8cf8b2 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2–4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf1f5a5d-79b0-4fc5-96f2-bd5119b56e2a (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2 to 4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff6805bb-b5f0-46d3-bf1d-3333b63ff1ae (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2 to 4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:252ba4e0-8dc3-43e3-be00-32570dc095bd (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2 to 4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:097424ef-612f-4bc2-809a-e5bb8eeae244 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2 to 4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:31618a34-b87b-484c-8b65-1f77d8cd0f28 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2 to 4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0874340a-75a1-4ac9-b224-80c5c24e1b41 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2 to 4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7c21db4d-6b9b-36c3-e053-2991aa0a0fd9 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2 to 4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8948b81f-401c-478e-bb3d-3b0368f5ed8b (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2 to 4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de67216c-4579-434e-b388-5e9b104f127a (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2 to 4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:410bf280-838d-45af-9b60-15f94ded7581 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2–4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:65ddb8b3-19d4-482f-8aec-49dc167a4c40 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2 to 4 hours in normal subjects, whether given intravenously or orally.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:212897cb-7de7-4711-aaf4-44234f950e9f (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The half-life of elimination ranges from 2 to 4 hours in normal subjects, whether given intravenously or orally.
2 to 5 hours
- Numeric value
- 2
- Unit
- hours
- Source records
- 30
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 30 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0effd04d-172c-5d8c-e063-6294a90a93f4 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The mean terminal elimination half-life of glipizide ranged from 2 to 5 hours after single or multiple doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ab2f4ea6-46e8-268a-e053-2995a90a3977 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The mean terminal elimination half-life of glipizide ranged from 2 to 5 hours after single or multiple doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5014a2d7-e0d3-4e84-9a3e-c90b398b8c6c (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The mean terminal elimination half-life of glipizide ranged from 2 to 5 hours after single or multiple doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4982f018-c53c-48ec-a4e8-4834228bcf2c (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The mean terminal elimination half-life of glipizide ranged from 2 to 5 hours after single or multiple doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:08b01608-73c2-45e0-8de4-c6c401261152 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The mean terminal elimination half-life of glipizide ranged from 2 to 5 hours after single or multiple doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bde478e6-e290-47e0-9241-ce88d927633e (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The mean terminal elimination half-life of glipizide ranged from 2 to 5 hours after single or multiple doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff9b3b7a-5ab1-45ec-e053-6294a90af426 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The mean terminal elimination half-life of glipizide ranged from 2 to 5 hours after single or multiple doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:548c1f50-dbf0-49cc-b58b-fcc5937affa8 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The mean terminal elimination half-life of glipizide ranged from 2 to 5 hours after single or multiple doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1b2ef6e2-5e7c-761e-e063-6294a90addd0 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The mean terminal elimination half-life of glipizide ranged from 2 to 5 hours after single or multiple doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:915636a4-092e-4e2e-9bc0-0d387d996977 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The mean terminal elimination half-life of glipizide ranged from 2 to 5 hours after single or multiple doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e593552f-9817-4cb5-b491-31ea57dea4b8 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The mean terminal elimination half-life of glipizide ranged from 2 to 5 hours after single or multiple doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:667dd68a-d3e7-4b50-bd0a-d17783a090d5 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The mean terminal elimination half-life of glipizide ranged from 2 to 5 hours after single or multiple doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aaf029d3-027e-4ae8-8ec5-3a4c16f9bd28 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The mean terminal elimination half-life of glipizide ranged from 2 to 5 hours after single or multiple doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:84794a52-b717-488c-8533-6425c83d405f (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The mean terminal elimination half-life of glipizide ranged from 2 to 5 hours after single or multiple doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:695c178f-77f0-451e-b718-72b65e495b7e (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The mean terminal elimination half-life of glipizide ranged from 2 to 5 hours after single or multiple doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0338aff9-29f9-405e-b516-06ef4b863863 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The mean terminal elimination half-life of glipizide ranged from 2 to 5 hours after single or multiple doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4afa67b2-7f86-4189-93a5-6a605f74540d (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The mean terminal elimination half-life of glipizide ranged from 2 to 5 hours after single or multiple doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0df8f606-97b3-463c-a132-338cf4630a71 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The mean terminal elimination half-life of glipizide ranged from 2 to 5 hours after single or multiple doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a34b58ac-42b2-4a19-a28b-cb3144ea55cd (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The mean terminal elimination half-life of glipizide ranged from 2 to 5 hours after single or multiple doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2aa01a7e-a703-426f-9cd3-70b88d0a8e7f (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The mean terminal elimination half-life of glipizide ranged from 2 to 5 hours after single or multiple doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0ffe361a-c99b-4f68-a7e2-a67a71c0c496 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The mean terminal elimination half-life of glipizide ranged from 2 to 5 hours after single or multiple doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:03151cb5-d32b-4484-8f2a-8c5d24c7f6f1 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The mean terminal elimination half-life of glipizide ranged from 2 to 5 hours after single or multiple doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0a1e1152-ade7-2092-e063-6394a90a99e7 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The mean terminal elimination half-life of glipizide ranged from 2 to 5 hours after single or multiple doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e4831ddb-9680-40cb-a060-4ba77c52d0aa (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The mean terminal elimination half-life of glipizide ranged from 2 to 5 hours after single or multiple doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:15308fc4-11e3-4cd5-8f04-ab8e3433cc7d (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The mean terminal elimination half-life of glipizide ranged from 2 to 5 hours after single or multiple doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ceb86ebb-d00a-4261-90ad-8751e799d93c (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The mean terminal elimination half-life of glipizide ranged from 2 to 5 hours after single or multiple doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4632b4ec-d2f1-40cc-8ef4-256413d8dbec (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The mean terminal elimination half-life of glipizide ranged from 2 to 5 hours after single or multiple doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c2aadc88-22d2-467c-b2cb-03efb5a1f1c1 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The mean terminal elimination half-life of glipizide ranged from 2 to 5 hours after single or multiple doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eed99b60-d043-4249-9b2a-f05e46fb588d (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The mean terminal elimination half-life of glipizide ranged from 2 to 5 hours after single or multiple doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0ccc17ca-fff8-0449-e063-6294a90af36d (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The mean terminal elimination half-life of glipizide ranged from 2 to 5 hours after single or multiple doses in patients with type 2 diabetes mellitus.
Projected row 689
- Medicine slug
- glipizide
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 107
- Source count
- 77
- Agreement rate
- 1
- Recorded readings
1 to 3 hours
- Numeric value
- 1
- Unit
- hours
- Source records
- 77
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 77 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:560448dd-3690-43d9-9667-925f20bb816e (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1 to 3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:95ea4c96-84b9-4515-9494-a93d26820f70 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1–3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f620559f-985b-421f-98df-bc2ca1cb0ece (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1 to 3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8c27962d-626b-30e6-e053-2a95a90a49c6 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1 to 3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dcf426b8-bcdc-8214-a1b6-6388bd3399a0 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1 to 3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3d87cc75-7a0d-46a2-e063-6294a90a6d49 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1–3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4d490a3a-abdc-4ff4-83fb-f302f51e3023 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1–3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c829b7bf-1a12-44b2-b5ce-fd44a1f0d333 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1 to 3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5ca7e38b-84cb-4043-b97e-e2f5cd82b442 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1–3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e0de2d19-b24b-46af-a10e-0b78c51350a4 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1–3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:abab5b07-08eb-4416-ae03-3656a078caa2 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1 to 3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:64c2a82f-014c-47d7-b303-23531e6bb723 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1 to 3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:213c4e61-9bb7-9d1b-e063-6394a90a7339 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1 to 3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:87cd4930-ba68-4acf-bf74-619c477b557d (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1–3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3b111484-78ef-4db9-95ee-6cc4b6acdd59 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1–3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0ed5ed22-dd53-495d-bc10-0bede4d87926 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1 to 3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e954afb8-52eb-416a-8f1b-14b0fcb3bac2 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1–3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d3b5677c-2265-47c8-beeb-bf12106056ba (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1 to 3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1b2e5656-9da9-4fab-bf01-ed75896b836a (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1 to 3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d6c016f7-bf93-4322-a179-d4798234b381 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1 to 3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c16edad6-4271-6ff0-e053-2a95a90a0240 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1 to 3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:06fb6c56-5609-41d9-8389-eba81432218d (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1–3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:62d569b8-bb34-0e06-e053-2a91aa0a2ae1 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1 to 3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:383540fd-2931-49bf-8009-25e8f7fc9bda (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1 to 3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a38cfe61-4aa5-498c-bca5-03a8213303bb (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1 to 3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9c9a3688-6de9-41db-af82-c4aa9b5b3f92 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1 to 3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51b35391-7672-c02f-e063-6294a90af54e (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1 to 3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c4dfe64-d1c5-65ec-e063-6394a90aead5 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1–3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:99af53db-e102-427a-a5a2-be1e69b3152d (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1 to 3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16fb8bc7-1db1-477e-a201-b3b678b8a84c (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1 to 3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6427db20-6783-439f-8c2d-64d1a6fcb9fc (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1–3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9f7f880a-1060-431a-a155-884e8cfbdf22 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1 to 3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f280acc1-d912-4f2e-b131-440e708c7b1f (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1 to 3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:be20727f-2724-457a-89ac-aa96604a0015 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1 to 3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aa1b16bf-e01c-d539-e053-2995a90a2735 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1 to 3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c8cfd137-7b41-460f-a463-141c9d1985ff (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1–3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:53e650f1-f755-e3ad-e063-6294a90ae309 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1 to 3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d91d021f-f644-eac7-e053-2995a90a81c4 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1 to 3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a59e2aaf-692c-4696-817b-3fed7a9dc52c (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1 to 3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f5d7a98c-d1d4-43b9-8d7e-830a33ae0c24 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1–3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:afb65cc1-a4fb-4771-b09c-dcf6e8c5786e (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1 to 3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0b29837b-c39b-16d2-e063-6394a90abe61 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1 to 3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6282c653-9e9c-6810-e053-2991aa0a4a8e (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1 to 3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c0db4c38-6eed-49ca-84ab-7ed89e476822 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1 to 3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c582d7d0-4db0-4296-8131-baefd1a671b2 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1–3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:589dc76d-c347-0589-e053-2991aa0a2520 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1 to 3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e295cbc-37c1-4e25-e054-00144ff8d46c (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1 to 3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5c627a52-e4ca-7103-e053-2a91aa0ae13f (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1 to 3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:155216cf-4bad-479a-83b6-032d4bd11c2e (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1–3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:02857195-33e9-4c1f-9e5f-7cc62f283649 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1 to 3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3de8b0a7-b848-40af-8406-fe6924ff41db (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1–3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ad55dfd7-ffb5-478a-aa84-1009fa921e22 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1 to 3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf5ff427-3ee4-4064-a55e-35daa2f12a06 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1 to 3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:86e6583c-b290-e2b5-e053-2991aa0ab485 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1 to 3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d5398166-5698-4ee5-bd41-3c24e4445b53 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1 to 3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:00729e82-150a-464a-abe7-a3319721fbdb (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1 to 3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9b405ff3-6ce5-460a-9406-db92e0e6ab1b (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1–3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:376ce3cf-4e1b-4b5f-b3e7-cc9fc4a5aeb4 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1 to 3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9b6464f-6fe6-446e-8150-d0c15c46fee8 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1–3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f60b0690-aca9-40ec-956e-bd2ecc35ec54 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1 to 3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4995328f-287c-4d4a-9b5f-9d354cc530fb (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1 to 3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b31ab6dd-0277-43ee-a054-f20c462f0c56 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1 to 3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3bb3b80a-30e8-62fe-e054-00144ff8d46c (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1 to 3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:116ffc6a-735c-49e0-a9d5-69b6bc3e3706 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1 to 3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:69a21bd3-3364-4035-b098-3808cc8cf8b2 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1–3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf1f5a5d-79b0-4fc5-96f2-bd5119b56e2a (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1 to 3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff6805bb-b5f0-46d3-bf1d-3333b63ff1ae (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1 to 3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:252ba4e0-8dc3-43e3-be00-32570dc095bd (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1 to 3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:097424ef-612f-4bc2-809a-e5bb8eeae244 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1 to 3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:31618a34-b87b-484c-8b65-1f77d8cd0f28 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1 to 3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0874340a-75a1-4ac9-b224-80c5c24e1b41 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1 to 3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7c21db4d-6b9b-36c3-e053-2991aa0a0fd9 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1 to 3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8948b81f-401c-478e-bb3d-3b0368f5ed8b (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1 to 3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de67216c-4579-434e-b388-5e9b104f127a (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1 to 3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:410bf280-838d-45af-9b60-15f94ded7581 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1–3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:65ddb8b3-19d4-482f-8aec-49dc167a4c40 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1 to 3 hours after a single oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:212897cb-7de7-4711-aaf4-44234f950e9f (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur 1 to 3 hours after a single oral dose.
Projected row 690
- Medicine slug
- glipizide
- Compared field
- volumeOfDistribution
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 107
- Source count
- 107
- Agreement rate
- 0.719626
- Recorded readings
11 liters
- Numeric value
- 11
- Unit
- L
- Source records
- 77
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 77 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:560448dd-3690-43d9-9667-925f20bb816e (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:95ea4c96-84b9-4515-9494-a93d26820f70 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f620559f-985b-421f-98df-bc2ca1cb0ece (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8c27962d-626b-30e6-e053-2a95a90a49c6 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dcf426b8-bcdc-8214-a1b6-6388bd3399a0 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3d87cc75-7a0d-46a2-e063-6294a90a6d49 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4d490a3a-abdc-4ff4-83fb-f302f51e3023 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c829b7bf-1a12-44b2-b5ce-fd44a1f0d333 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5ca7e38b-84cb-4043-b97e-e2f5cd82b442 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e0de2d19-b24b-46af-a10e-0b78c51350a4 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:abab5b07-08eb-4416-ae03-3656a078caa2 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:64c2a82f-014c-47d7-b303-23531e6bb723 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:213c4e61-9bb7-9d1b-e063-6394a90a7339 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:87cd4930-ba68-4acf-bf74-619c477b557d (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3b111484-78ef-4db9-95ee-6cc4b6acdd59 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0ed5ed22-dd53-495d-bc10-0bede4d87926 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e954afb8-52eb-416a-8f1b-14b0fcb3bac2 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d3b5677c-2265-47c8-beeb-bf12106056ba (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1b2e5656-9da9-4fab-bf01-ed75896b836a (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d6c016f7-bf93-4322-a179-d4798234b381 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c16edad6-4271-6ff0-e053-2a95a90a0240 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:06fb6c56-5609-41d9-8389-eba81432218d (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:62d569b8-bb34-0e06-e053-2a91aa0a2ae1 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:383540fd-2931-49bf-8009-25e8f7fc9bda (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a38cfe61-4aa5-498c-bca5-03a8213303bb (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9c9a3688-6de9-41db-af82-c4aa9b5b3f92 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51b35391-7672-c02f-e063-6294a90af54e (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c4dfe64-d1c5-65ec-e063-6394a90aead5 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:99af53db-e102-427a-a5a2-be1e69b3152d (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16fb8bc7-1db1-477e-a201-b3b678b8a84c (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6427db20-6783-439f-8c2d-64d1a6fcb9fc (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9f7f880a-1060-431a-a155-884e8cfbdf22 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f280acc1-d912-4f2e-b131-440e708c7b1f (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:be20727f-2724-457a-89ac-aa96604a0015 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aa1b16bf-e01c-d539-e053-2995a90a2735 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c8cfd137-7b41-460f-a463-141c9d1985ff (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:53e650f1-f755-e3ad-e063-6294a90ae309 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d91d021f-f644-eac7-e053-2995a90a81c4 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a59e2aaf-692c-4696-817b-3fed7a9dc52c (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f5d7a98c-d1d4-43b9-8d7e-830a33ae0c24 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:afb65cc1-a4fb-4771-b09c-dcf6e8c5786e (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0b29837b-c39b-16d2-e063-6394a90abe61 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6282c653-9e9c-6810-e053-2991aa0a4a8e (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c0db4c38-6eed-49ca-84ab-7ed89e476822 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c582d7d0-4db0-4296-8131-baefd1a671b2 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:589dc76d-c347-0589-e053-2991aa0a2520 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e295cbc-37c1-4e25-e054-00144ff8d46c (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5c627a52-e4ca-7103-e053-2a91aa0ae13f (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:155216cf-4bad-479a-83b6-032d4bd11c2e (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:02857195-33e9-4c1f-9e5f-7cc62f283649 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3de8b0a7-b848-40af-8406-fe6924ff41db (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ad55dfd7-ffb5-478a-aa84-1009fa921e22 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf5ff427-3ee4-4064-a55e-35daa2f12a06 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:86e6583c-b290-e2b5-e053-2991aa0ab485 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d5398166-5698-4ee5-bd41-3c24e4445b53 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:00729e82-150a-464a-abe7-a3319721fbdb (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9b405ff3-6ce5-460a-9406-db92e0e6ab1b (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:376ce3cf-4e1b-4b5f-b3e7-cc9fc4a5aeb4 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9b6464f-6fe6-446e-8150-d0c15c46fee8 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f60b0690-aca9-40ec-956e-bd2ecc35ec54 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4995328f-287c-4d4a-9b5f-9d354cc530fb (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b31ab6dd-0277-43ee-a054-f20c462f0c56 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3bb3b80a-30e8-62fe-e054-00144ff8d46c (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:116ffc6a-735c-49e0-a9d5-69b6bc3e3706 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:69a21bd3-3364-4035-b098-3808cc8cf8b2 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf1f5a5d-79b0-4fc5-96f2-bd5119b56e2a (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff6805bb-b5f0-46d3-bf1d-3333b63ff1ae (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:252ba4e0-8dc3-43e3-be00-32570dc095bd (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:097424ef-612f-4bc2-809a-e5bb8eeae244 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:31618a34-b87b-484c-8b65-1f77d8cd0f28 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0874340a-75a1-4ac9-b224-80c5c24e1b41 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7c21db4d-6b9b-36c3-e053-2991aa0a0fd9 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8948b81f-401c-478e-bb3d-3b0368f5ed8b (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de67216c-4579-434e-b388-5e9b104f127a (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:410bf280-838d-45af-9b60-15f94ded7581 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:65ddb8b3-19d4-482f-8aec-49dc167a4c40 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:212897cb-7de7-4711-aaf4-44234f950e9f (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
The apparent volume of distribution of glipizide after intravenous administration was 11 liters, indicative of localization within the extracellular fluid compartment.
10 liters
- Numeric value
- 10
- Unit
- L
- Source records
- 30
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 30 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0effd04d-172c-5d8c-e063-6294a90a93f4 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution was approximately 10 liters after single intravenous doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ab2f4ea6-46e8-268a-e053-2995a90a3977 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution was approximately 10 liters after single intravenous doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5014a2d7-e0d3-4e84-9a3e-c90b398b8c6c (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution was approximately 10 liters after single intravenous doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4982f018-c53c-48ec-a4e8-4834228bcf2c (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution was approximately 10 liters after single intravenous doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:08b01608-73c2-45e0-8de4-c6c401261152 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution was approximately 10 liters after single intravenous doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bde478e6-e290-47e0-9241-ce88d927633e (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution was approximately 10 liters after single intravenous doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff9b3b7a-5ab1-45ec-e053-6294a90af426 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution was approximately 10 liters after single intravenous doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:548c1f50-dbf0-49cc-b58b-fcc5937affa8 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution was approximately 10 liters after single intravenous doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1b2ef6e2-5e7c-761e-e063-6294a90addd0 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution was approximately 10 liters after single intravenous doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:915636a4-092e-4e2e-9bc0-0d387d996977 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution was approximately 10 liters after single intravenous doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e593552f-9817-4cb5-b491-31ea57dea4b8 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution was approximately 10 liters after single intravenous doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:667dd68a-d3e7-4b50-bd0a-d17783a090d5 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution was approximately 10 liters after single intravenous doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aaf029d3-027e-4ae8-8ec5-3a4c16f9bd28 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution was approximately 10 liters after single intravenous doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:84794a52-b717-488c-8533-6425c83d405f (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution was approximately 10 liters after single intravenous doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:695c178f-77f0-451e-b718-72b65e495b7e (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution was approximately 10 liters after single intravenous doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0338aff9-29f9-405e-b516-06ef4b863863 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution was approximately 10 liters after single intravenous doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4afa67b2-7f86-4189-93a5-6a605f74540d (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution was approximately 10 liters after single intravenous doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0df8f606-97b3-463c-a132-338cf4630a71 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution was approximately 10 liters after single intravenous doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a34b58ac-42b2-4a19-a28b-cb3144ea55cd (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution was approximately 10 liters after single intravenous doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2aa01a7e-a703-426f-9cd3-70b88d0a8e7f (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution was approximately 10 liters after single intravenous doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0ffe361a-c99b-4f68-a7e2-a67a71c0c496 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution was approximately 10 liters after single intravenous doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:03151cb5-d32b-4484-8f2a-8c5d24c7f6f1 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution was approximately 10 liters after single intravenous doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0a1e1152-ade7-2092-e063-6394a90a99e7 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution was approximately 10 liters after single intravenous doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e4831ddb-9680-40cb-a060-4ba77c52d0aa (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution was approximately 10 liters after single intravenous doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:15308fc4-11e3-4cd5-8f04-ab8e3433cc7d (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution was approximately 10 liters after single intravenous doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ceb86ebb-d00a-4261-90ad-8751e799d93c (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution was approximately 10 liters after single intravenous doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4632b4ec-d2f1-40cc-8ef4-256413d8dbec (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution was approximately 10 liters after single intravenous doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c2aadc88-22d2-467c-b2cb-03efb5a1f1c1 (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution was approximately 10 liters after single intravenous doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eed99b60-d043-4249-9b2a-f05e46fb588d (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution was approximately 10 liters after single intravenous doses in patients with type 2 diabetes mellitus.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0ccc17ca-fff8-0449-e063-6294a90af36d (opens source in a new tab)
Glipizide label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution was approximately 10 liters after single intravenous doses in patients with type 2 diabetes mellitus.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=680Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.